What is the current Vaccinex market capitalization?
The current market capitalization of Vaccinex is 1.18 M USD.
Vaccinex Market capitalization 2024
Vaccinex Market capitalization
1.18 M USD
Ticker
VCNX
ISIN
US9186401033
WKN
A2N30M
In 2024, Vaccinex's market cap stood at 1.18 M USD, a -80.66% increase from the 6.11 M USD market cap in the previous year.
The Vaccinex Market capitalization history
| YEAR | Market Capitalization (undefined USD) |
|---|---|
| 2023 | 29.52 |
| 2022 | 42.95 |
| 2021 | 69.54 |
| 2020 | 76.41 |
| 2019 | 69.78 |
| 2018 | 83.92 |
| 2017 | - |
| 2016 | - |
Vaccinex Aktienanalyse
What does Vaccinex do?
Vaccinex Inc is a biopharmaceutical company based in Rochester, New York, focusing on the development of novel therapies for a variety of diseases. The company was founded in 2001 by Maurice Zylofo and Dr. Steffen Nock, and has since built an impressive track record in drug development. Vaccinex's business model is based on the discovery and development of specific monoclonal antibodies for the treatment of diseases, particularly cancer. The company has developed a proprietary platform technology called ActivMAb®, which quickly and efficiently identifies potential targets and develops specific antibodies to block or modulate these targets. Vaccinex has several business divisions, including cancer therapy, immunology, cardiology, and neurology. Each of these divisions focuses on specific diseases and potential applications of Vaccinex's technology. The company also has partnerships with other industry leaders, such as Bristol-Myers Squibb and Catalent, to support the development and manufacturing of new drugs. The company has conducted several clinical trials to evaluate the efficacy and safety of its products. Vaccinex's most promising products are VX15/2503, a monoclonal antibody targeting cancer, and PEPCON, a potential vaccine for Alzheimer's disease. VX15/2503 is an antibody that targets the semaphorin 4-D receptor, a molecule that plays a key role in cancer development. The drug has shown in preclinical studies that it can inhibit tumor growth and has shown promise in clinical trials for the treatment of lung cancer and an aggressive brain tumor called glioblastoma. PEPCON is a novel vaccine targeting Alzheimer's disease. The vaccine aims to eliminate the beta-amyloid peptide, which is deposited in the brains of patients with Alzheimer's disease. The drug has shown in early clinical studies that it is able to reduce these brain deposits, which may lead to improved cognitive function. Overall, Vaccinex Inc has a promising future and is well-positioned to develop new and innovative therapies for the treatment of diseases. The company has an impressive track record in drug development and partnering with other industry leaders to support the manufacturing and commercialization of new drugs. With a strong pipeline of promising drug candidates, Vaccinex Inc will continue to play an important role in the development of new treatments. Vaccinex ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Vaccinex's Market Capitalization
Vaccinex's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Vaccinex's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Vaccinex's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Vaccinex’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Vaccinex stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Vaccinex.
How has the market capitalization of Vaccinex developed in recent years?
The market capitalization of Vaccinex has increased/decreased by -80.66% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Vaccinex?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Vaccinex?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Vaccinex have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Vaccinex pay?
Over the past 12 months, Vaccinex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vaccinex is expected to pay a dividend of 0 USD.
What is the dividend yield of Vaccinex?
The current dividend yield of Vaccinex is .
When does Vaccinex pay dividends?
Vaccinex pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Vaccinex?
Vaccinex paid dividends every year for the past 0 years.
What is the dividend of Vaccinex?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Vaccinex located?
Vaccinex is assigned to the 'Health' sector.
Wann musste ich die Aktien von Vaccinex kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Vaccinex from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
When did Vaccinex pay the last dividend?
The last dividend was paid out on 10/5/2024.
What was the dividend of Vaccinex in the year 2023?
In the year 2023, Vaccinex distributed 0 USD as dividends.
In which currency does Vaccinex pay out the dividend?
The dividends of Vaccinex are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Vaccinex
Our stock analysis for Vaccinex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaccinex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
